Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myelomaJoaquín Martínez‐López, Constanza Celia Nieto Marín, M-T Cedena et al.|Leukemia|2017Cited by 51
A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemiaEsther Onecha, Rosa Ayala, María Linares et al.|Haematologica|2018Cited by 51
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencingYanira Ruiz‐Heredia, Joaquín Martínez‐López, Beatriz Sánchez-Vega et al.|Haematologica|2018Cited by 15
Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma PatientsBeatriz Sánchez-Vega, Joaquín Martínez‐López, Rafael Alonso et al.|Blood|2016Cited by 4